X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net Proceeds will be utilized to accelerate the clinical advancement of the Nectero EAST (pentagalloyl glucose) for the treatment abdominal aortic aneurysms.
Lead Product(s): Pentagalloyl Glucose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nectero EAST
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Norwest Venture Partners
Deal Size: $96.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing April 11, 2024
Details:
Nectero EAST System is comprised of a dual-balloon delivery catheter and stabilizer mixture containing pentagalloyl glucose (PGG). It delivers PGG locally into the aneurysmal wall. It is under phase 2/3 for treatment of small- to medium-sized Abdominal Aortic Aneurysms.
Lead Product(s): Pentagalloyl Glucose
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nectero EAST
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
